Literature DB >> 26928148

Randomized controlled trial of prolonged second stage: extending the time limit vs usual guidelines.

Alexis C Gimovsky1, Vincenzo Berghella2.   

Abstract

BACKGROUND: Guidelines for management of the second stage have been proposed since the 1800s and were created largely by expert opinion. Current retrospective data are mixed regarding differences in maternal and neonatal outcomes with a prolonged second stage. There are no randomized controlled trials that have evaluated whether extending the second stage of labor beyond current American College of Obstetricians and Gynecologists recommendations is beneficial.
OBJECTIVE: The purpose of this study was to evaluate whether extending the length of labor in nulliparous women with prolonged second stage affects the incidence of cesarean delivery and maternal and neonatal outcomes. STUDY
DESIGN: We conducted a randomized controlled trial of nulliparous women with singleton gestations at 36 0/7 to 41 6/7 weeks gestation who reached the American College of Obstetricians and Gynecologists definition of prolonged second stage of labor, which is 3 hours with epidural anesthesia or 2 hours without epidural anesthesia. Women were assigned randomly to extended labor for at least 1 additional hour, or to usual labor, which was defined as expedited delivery via cesarean or operative vaginal delivery. The exclusion criteria were intrauterine fetal death, planned cesarean delivery, age <18 years, and suspected major fetal anomaly. Primary outcome was incidence of cesarean delivery. Maternal and neonatal outcomes were compared secondarily. Statistical analysis was done by intention-to-treat.
RESULTS: Seventy-eight nulliparous women were assigned randomly. All of the women had epidural anesthesia. Maternal demographics were not significantly different. The incidence of cesarean delivery was 19.5% (n = 8/41 deliveries) in the extended labor group and 43.2% (n = 16/37 deliveries) in the usual labor group (relative risk, 0.45; 95% confidence interval, 0.22-0.93). The number needed-to-treat to prevent 1 cesarean delivery was 4.2. There were no statistically significant differences in maternal or neonatal morbidity outcomes.
CONCLUSION: Extending the length of labor in nulliparous women with singleton gestations, epidural anesthesia, and prolonged second stage decreased the incidence of cesarean delivery by slightly more than one-half, compared with usual guidelines. Maternal or neonatal morbidity were not statistically different between the groups; however, our study was underpowered to detect small, but potentially clinical important, differences.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cesarean delivery; labor; prolonged second stage; randomized controlled trial; second stage of labor

Mesh:

Year:  2016        PMID: 26928148     DOI: 10.1016/j.ajog.2015.12.042

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  New labor management guidelines and changes in cesarean delivery patterns.

Authors:  Joshua I Rosenbloom; Molly J Stout; Methodius G Tuuli; Candice L Woolfolk; Julia D López; George A Macones; Alison G Cahill
Journal:  Am J Obstet Gynecol       Date:  2017-10-14       Impact factor: 8.661

2.  Cesarean in the second stage: a possible risk factor for subsequent spontaneous preterm birth.

Authors:  Vincenzo Berghella; Alexis C Gimovsky; Lisa D Levine; Joy Vink
Journal:  Am J Obstet Gynecol       Date:  2017-07       Impact factor: 8.661

Review 3.  A Rare Complication during Vaginal Delivery, Hamman's Syndrome: A Case Report and Systematic Review of Case Reports.

Authors:  Marco La Verde; Adriano Palmisano; Irene Iavarone; Carlo Ronsini; Domenico Labriola; Stefano Cianci; Ferdinando Schettino; Alfonso Reginelli; Gaetano Riemma; Pasquale De Franciscis
Journal:  Int J Environ Res Public Health       Date:  2022-04-12       Impact factor: 4.614

4.  Redefining Second Stage of Labor: Number of Pushing Contractions.

Authors:  Serin M Bok; Gabriela E Pena Carmona; Jake Crawford; Ramy Eskander; Mina Desai; Michael G Ross
Journal:  AJP Rep       Date:  2020-06-19

5.  The hazards of conducting induction of labour in high-risk pregnancies at district hospitals in low- and middle-income countries: lessons to learn from a case report.

Authors:  Nnabuike Chibuoke Ngene; Jagidesa Moodley
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

6.  Influence of the second stage of labor on maternal and neonatal outcomes in vaginal births after caesarean section: a multicenter study in Germany.

Authors:  G Gitas; L Proppe; A K Ertan; S Baum; A Rody; M Kocaer; K Dinas; L Allahqoli; A S Laganà; A Sotiriadis; S Sommer; I Alkatout
Journal:  BMC Pregnancy Childbirth       Date:  2021-05-04       Impact factor: 3.007

7.  Epidural analgesia during labor and its optimal initiation time-points: A real-world study on 400 Chinese nulliparas.

Authors:  Ying Zha; Xun Gong; Chengwu Yang; Dongrui Deng; Ling Feng; Ailin Luo; Li Wan; Fuyuan Qiao; Wanjiang Zeng; Suhua Chen; Yuanyuan Wu; Dongji Han; Haiyi Liu
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

8.  Aspects of Pelvic Floor Protection in Spontaneous Delivery - a Review.

Authors:  Markus Hübner; Christiane Rothe; Claudia Plappert; Kaven Baeßler
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-04-05       Impact factor: 2.915

9.  Understanding Factors Leading to Primary Cesarean Section and Vaginal Birth After Cesarean Delivery in the Friuli-Venezia Giulia Region (North-Eastern Italy), 2005-2015.

Authors:  L Cegolon; G Mastrangelo; G Maso; G Dal Pozzo; L Ronfani; A Cegolon; W C Heymann; F Barbone
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

10.  The impact of stage of labor on adverse maternal and neonatal outcomes in multiparous women: a retrospective cohort study.

Authors:  Li Wang; Hongxia Wang; Lu Jia; Wenjie Qing; Fan Li; Jie Zhou
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-07       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.